Key joint structures affected
Improvement in knee strength*
Improvement in cartilage thickness*
Improvement in joint comfort, function, and stiffness*
Shown to preserve and improve 5 key joint structures: Cartilage, Menisci, Ligaments, Synovium, and Subchondral bone* |
|
Kinexa has also been down to improve knee strength and functional performance* |
|
24% improvement in knee strength* |
|
10% improvement in cartilage thickness* |
|
4% improvement in cartilage composition* |
|
Greater than 26% improvement in functional mobility* |
|
Greater than 49% improvement in joint comfort, function and stiffness* |
VEGAN
GLUTEN-FREE
NON-GMO

SOLVENT-FREE
A revered Ayurvedic herb known as the "King of Medicines"

A member of the ginger family, primarily known a a key ingredient in curry powder.
A potent Ayurvedic resin for thousands of years to reduce chronic inflammation
Rhodiola rosea is a plant native to remote Arctic climates in Asia, Europe and North America.

The root of the plant contains around 140 chemical compounds including phenols, rosavin, rosarin, salidroside and more.
Kale chips cold-pressed put a bird on it mumblecore kogi brooklyn farm-to-table blue bottle yuccie authentic kombucha migas. Literally tilde tacos paleo.

Kale chips cold-pressed put a bird on it mumblecore kogi brooklyn farm-to-table blue bottle yuccie authentic kombucha migas. Literally tilde tacos paleo.
In the new clinical study, 100 subjects aged 40–75 with Grade II or III osteoarthritis received 200 mg/day of Kinexa or a matching placebo for six months. Assessments occurred at baseline, 1, 2, 4, and 6 months. Key subjective outcomes included WOMAC, VAS, and Lequesne Functional Index (LFI) scores. Functional measures included isometric knee torque, a 6-minute walk test, and a Timed Get Up and Go test. Advanced imaging assessed cartilage volume and thickness (MRI), cartilage composition (dGEMRIC MRI), and Whole Organ Magnetic Resonance Imaging Score (WORMS), a semi-quantitative MRI scoring of whole-joint structural integrity, which includes subchondral bone. Biomarkers of inflammation and cartilage metabolism were also evaluated.

Kinexa significantly improved average Knee Extensor Torque across the 3 angles assessed (30°, 60°, 90°) vs. baseline and placebo at Days 30, 60, 120 and 180.
*Knee joint torque improved 24% relative to baseline in the Kinexa cohort over the 6-month study.

Cartilage thickness, assessed by MRI, was significantly improved vs baseline and vs placebo in the Kinexa group, while in the placebo group, cartilage thickness significantly declined over the 6-month study.
*Cartilage thickness improved 10% relative to baseline in the Kinexa.

Cartilage volume, assessed by MRI, significantly improved vs baseline in the Kinexa group, while in the placebo group, cartilage volume significantly declined versus baseline over the 6-month study.

Cartilage composition, evaluated as glycosaminoglycan concentration via dGEMRIC-enhanced MRI, was significantly improved vs baseline and vs placebo in the Kinexa group. In the placebo group, the concentration of glycosaminoglycans in cartilage significantly declined over the 6-month study.
*Glycosaminoglycan concentration of cartilage improved 4% relative to baseline in the Kinexa group.

Subchondral Bone WORMS Composite Scores improved significantly versus baseline and placebo for the Kinexa group, while the placebo declined significantly over the 6-month study.
WORMS Subchondral Bone Composite Score is comprised of bone lesion, cysts, osteophyte and attrition scores.

Kinexa significantly improved average walking speed in the Six-Minute Walk Test versus baseline and placebo at Days 30, 60, 120, and 180.
*Walking Speed improved 33% relative to baseline in the Kinexa group over the 6-month study.

Ligament & Menisci WORMS Composite Score improved significantly versus baseline and placebo for the Kinexa group, while the placebo scores declined significantly over the 6-month study.
WORMS Ligament & Menisci Composite Score is comprised of anterior/posterior cruciate and medial/lateral collateral ligaments.

Kinexa significantly improved Total WOMAC versus baseline and placebo at Days 30, 60, 120, and 180.
All WOMAC Subsets (Pain, Stiffness and Function) were also significantly improved with Kinexa versus baseline and placebo at Days 30, 60, 120 and 180.
*Total WOMAC improved 56% relative to baseline in the Kinexa group over the 6-month study.

Synovial Health WORMS Composite Scores improved significantly versus baseline and placebo for the Kinexa group, while the placebo scores declined significantly over the 6-month study.
WORMS Synovial Health Composite Score includes synovitis, effusion, periarticular cysts and loose bodies.
Over a six-month study, Kinexa was shown to preserve and improve five key joint structures: Cartilage, Menisci, Ligaments, Synovium, and Subchondral bone*
Kinexa opens up a new segment of the joint health category: whole joint health. It goes beyond managing symptoms toward a new understanding of bone and joint health, addressing a much broader range of factors that contribute to joint health and mobility.
When cartilage, meniscus, ligaments, and the foundation beneath the cartilage stay strong and resilient, the joint can absorb shock, distribute load evenly and remain stable through everyday life, training, aging, and wear-and-tear.
Kinexa addresses new realms of mobility improvement starting with comfort and flexibility and adding the potential for long-term protection.
.jpg)
Kinexa is a new type of ingredient in the joint health space, supported by a clinical study that focuses on ‘whole joint structure. Most of today’s ingredients have science centered on comfort, stiffness, flexibility and function – based on subjective testing. Kinexa’s unique functionality and clinical work puts it in a position to be combined with these ingredients to create a new ‘stack’ for joint health.
A great example of this would be pairing 200 mg/day of Kinexa with PLT’s AprèsFlex 5-Day Joint Support. One of the leading joint health ingredients in the world, AprèsFlex is supported by four clinical studies that demonstrate joint comfort and other measures in just 5 days at a remarkably low 100 mg/day dose. This stack will offer consumers fast, experiential support plus objectively measured, imaging-validated structural benefits that support joint longevity.
![]()
Jennifer Murphy, MS, RD, Head of Innovation & Clinical Science for PLT Health Solutions
Joint longevity is structural. PLT Health Solutions would love to initiate a dialogue with you about how this new ingredient and new study can create an entire new range of options of consumer product development supporting joint health.